Part, Chapter, Paragraph
1 -, 1 | all the available data (see Appendix 5) for preparing
2 I, 2. 10. 1 | the field of cancer. As we see a clear need to adjust concepts
3 I, 2. 10. 2(4) | See: htt m.~
4 I, 2. 10. 2(5) | See: htt t. Org/44.~
5 I, 3. 2 | and Malta. Sweden will see a population growth between
6 II, 4. 1 | France and Italy in 2005 (see above).~ ~All health expectancy
7 II, 4. 1 | through the EHEMU projects (see www. eu and www. ~ ~Further
8 II, 5. 1. 1 | conditions and problems~See section 5.6.~Respiratory
9 II, 5. 2. 3 | Table 5.2.4; here we can see mean attack rates of 10-
10 II, 5. 2. 4 | Eastern and Eastern countries (see also Chapter 8).~ ~Table
11 II, 5. 2. 4 | glycaemia (Panico et al, 2008) (see Chapter 5.1.4). Recent evidence
12 II, 5. 2. 4 | in predicting CV risk (see also Chapter 10).~ ~Table
13 II, 5. 2. 4 | and psychosocial stress (see the attached European Heart
14 II, 5. 2. 4 | have never been smokers (see Chapter 5.1.2.).~Unfortunately,
15 II, 5. 2. 5 | body weight) or the environment see Sections 5.1. or 5.2.; for
16 II, 5. 2. 5 | for diabetes mellitus see Section 3.1.5. Annex 1 is
17 II, 5. 3. 2 | cancer registration coverage (see above). Yet in several EU
18 II, 5. 3. 2 | estimates of cancer incidence. See: http://www.iarc.fr~ ~ENCR –
19 II, 5. 3. 2 | health-care planning and research. See: http://www.encr.com.fr/~ ~
20 II, 5. 3. 2 | health information systems. See: www.tumori.net/eurochip/~ ~
21 II, 5. 3. 2 | into the current decade. See: http://www.eurocare.it/~ ~
22 II, 5. 3. 2 | to EU 2015 Cancer Target. See: http://www.eurocanplus.
23 II, 5. 3. 2 | and guidelines on cancer. See: http://www.esmo.org/resources/
24 II, 5. 3. 2 | availability of new cancer drugs. See: http://annonc.oxfordjournals.
25 II, 5. 3. 7 | disease (Boyle et al, 2003).~ ~See Chapter 10 for primary prevention
26 II, 5. 3. 7 | environment. For further details see Chapter 4.14.~ ~
27 II, 5. 3. 7 | number of EU Member States (see Table 5.3.2) consider national
28 II, 5. 4. 2 | Greenfield et al 2004, see Table 5.4.2), only three
29 II, 5. 4. 2 | Glycated HaemoglobinHbA1c, see Armesto et al. 2006) due
30 II, 5. 4. 6 | use of BIRO technology (see “Future developments”).~
31 II, 5. 4. 6 | and healthy lifestyles. See Chapter 5.13. on overweight
32 II, 5. 4. 6 | pressure and high cholesterol, see Chapter 5.2.4. and for other
33 II, 5. 4. 6 | and for other risk factors see Chapter 10.~To prevent the
34 II, 5. 4. 6 | Luxembourg, 1-2 June 2006 (see Table 5.4.1);~ ~Table 5.
35 II, 5. 5. 1 | mental health data in HfA, see also the introductory Section
36 II, 5. 5. 3 | in-patients per 1,000 populations (see Figure 5.5.3.3.2), the value
37 II, 5. 5. 3 | AGREE Collaboration, 2003) – see table 5.5.3.2.4.~Table 5.
38 II, 5. 5. 3 | as for outpatient care (see Table 5.5.3.3.6). Since
39 II, 5. 5. 3 | reported in incidence studies (see above).~ ~Table 5.5.3.4.
40 II, 5. 5. 3 | of Good Practice on MS ( see below) calls for information
41 II, 5. 6. 3 | referral for (Lin et al, 2000), see physiotherapists and complementary
42 II, 5. 7. 5 | policies~ ~Primary prevention~ ~See Chapter 8~ ~Secondary prevention~ ~
43 II, 5. 7. 6 | improving organ donation rates ( see also the Chapter 9.2. on
44 II, 5. 9. 5 | lifestyles or the environment see Chapter 5. A key message
45 II, 5. 10. 2 | under Community legislation (see section 5). EuroPrevall
46 II, 5. 10. 3 | are intolerant to food (see section 5.10.3.1.) and the
47 II, 5. 11. 3 | cell tumours and others (See Chapter 4.3).~Some skin
48 II, 5. 11. 3 | such as metals in piercing (see Focus Box), perfumes and
49 II, 5. 11. 3 | joint European enterprises (see also Chapter 7 on “Rare Diseases”).~ ~
50 II, 5. 12. 4 | HBV and HCV) infection (see also Chapter 6) and alcohol
51 II, 5. 12. 4 | association with HBV and HCV (see Chapter 6), cirrhosis mortality
52 II, 5. 12. 5 | control of HCV transmission (see Chapter 6) and of alcohol
53 II, 5. 12. 5 | all European countries.~See Chapter 8 for what concerns
54 II, 5. 12. 5 | cause of disease and death ( see also Chapter 6).~ ~There
55 II, 5. 13 | For the quoted references, see Chapter 10.2.1.7.~ ~ ~
56 II, 5. 14. 5 | For the control of smoking see Chapter 8; for the control
57 II, 5. 14. 5 | excessive alcohol consumption see Chapter 8 ; and for diabetes
58 II, 5. 14. 5 | and for diabetes mellitus see Chapter 5.4.~It is possible
59 II, 5. 15. 1 | data are very much lacking (See: htt ~ ~Depending on the
60 II, 5. 15. 5 | initiatives on rare diseases.~(see: htt 93 and http ~ ~
61 II, 6. 3. 1 | infected, falls ill, goes to see a doctor, is diagnosed,
62 II, 6. 3. 4 | drug-resistant disease (see section on antimicrobial
63 II, 7. 2. 1 | reliability and quality see the ANAMORT project (htt ~ ~
64 II, 7. 2. 2 | discharge data for injuries see the final report of the
65 II, 7. 3 | Statistics summary 2003 – 2005” (see KfV, 2007)1. See also the
66 II, 7. 3 | 2005” (see KfV, 2007)1. See also the executive summary
67 II, 7. 3. 4 | place of occurrence etc. (see also “IDB” in Chapter 6.
68 II, 7. 3. 5 | medically treated cases (See Table 7.1).~ ~Suicide and
69 II, 7. 3. 5 | almost 61 000 people a year – see Figure 7.2 ) In Europe suicide
70 II, 7. 4 | standard of injury indicators.~(See: htt ~ ~Injury surveillance
71 II, 7. 4. 3 | an injury (Figure 7.20; see also Figure 7.8. Fatalities
72 II, 7. 4. 4 | due to sports activities (see Figure 7.14).This means
73 II, 7. 4. 4 | gymnastics and aerobics (7%). (see Figure 7.21).Swimming and
74 II, 8. 1. 2(1) | European Statistical System, see: htt AL~
75 II, 8. 1. 5(2) | Please see: htt ml~
76 II, 8. 2. 1 | of health inequalities (see the chapter on policies
77 II, 8. 2. 1(8) | See : ww rg~
78 II, 8. 2. 3 | Countries in the world (see a list of studies with their
79 II, 9 | and maternal education (see above). Data on the first
80 II, 9 | interactive data) (see also Section 10.2).~ ~Cannabis
81 II, 9 | interactive data) (see also Section 10.2).~ ~Sexual
82 II, 9. 1 | nearly half of the cases (see chapter 9.3.2).~ ~This burden
83 II, 9. 1. 1 | are not reproduced here (see below). The remaining 25%
84 II, 9. 1. 1 | Congenital malformations~ ~See Chapter 9.1.2 for a detailed
85 II, 9. 1. 1 | synthesis of available knowledge see Table 9.1 and the section
86 II, 9. 1. 1 | differently in EU Member States. See Chapter 9.3.2 for more information.~ ~ ~
87 II, 9. 1. 2 | elsewhere in this Report (see Chapter 5). Metabolic diseases
88 II, 9. 1. 2 | registers in 20 countries (see Table 9.1.2.2.1), covering
89 II, 9. 1. 2 | in others TOPFA is rare (see above). This has resulted
90 II, 9. 1. 2 | For main risk factors see Table 9.1a.~ ~Table 9.1a.
91 II, 9. 1. 2 | entities. Most rare diseases (see Chapter 5.15) are congenital.
92 II, 9. 2. 2 | its youngest age-group (see: htt ~ ~WHO (European Regional
93 II, 9. 2. 2 | definitions is important. (see:~www ~ ~European Commission:
94 II, 9. 2. 3 | countries in recent years (see Chapter 4.1). Congenital
95 II, 9. 2. 3 | of mortality in neonates (see Chapter 4.2), and accidents
96 II, 9. 2. 3 | accidents for 5-14 year olds (see Chapter 7).~ ~Cancer: Tumors
97 II, 9. 2. 3 | their health (WHO 2005c)(see also Chapter 9.3).~ ~The
98 II, 9. 2. 3 | increase in type two diabetes(see also Chapter 5).~ ~Excess
99 II, 9. 2. 3 | reasons for under-reporting (see below).~ ~There are frequently
100 II, 9. 2. 4 | identified for children health (see Table 9.1b.). Equally important -
101 II, 9. 2. 4 | and maternal education (see above). Data on the first
102 II, 9. 2. 4 | interactive data) (see also Section 10.2).~ ~Cannabis
103 II, 9. 2. 4 | interactive data) (see also Section 10.2).~ ~Sexual
104 II, 9. 3. 1 | dealt with in this Chapter see Chapter 9.5.~ ~ ~
105 II, 9. 3. 1 | accidents as compared to women (see Chapter on Accidents), with
106 II, 9. 3. 1 | concerning health services see Chapter 11.~ ~
107 II, 9. 3. 2 | synthesis of available knowledge see Table 9.1a.~ ~The EURO-PERISTAT
108 II, 9. 4. 3 | and more healthy years (see above), too many years are
109 II, 9. 4. 3 | significant risk factor in men (see chapter on dementia for
110 II, 9. 4. 5 | Indeed, some commentators see the creation of integrated
111 II, 9. 5. 2 | Injuries and Accidents).~See also section 9.2 for additional
112 II, 9. 5. 3 | Statistics On-line, 2007). (See Figure 9.5.3) Carers can
113 II, 9. 5. 3 | femininities can limit the way they see themselves as male and female (
114 II, 9. 5. 3 | and tend to stay longer (See: htt ~ ~
115 III, 10. 2. 1 | of deaths in both sexes (see Chapter 5.2.). Smoking contributes
116 III, 10. 2. 1 | et al., 1998).~Cancers (see Chapter 5.3) of the respiratory
117 III, 10. 2. 1 | Mortality due to COPD (see Chapter 5.7) varies from
118 III, 10. 2. 1(1) | Substances. (For further details see http://eldd.emcdda.europa.
119 III, 10. 2. 1(5) | See EMCDDA’s 2006 selected issues
120 III, 10. 2. 1 | highest prevalence levels. See Figure 10.2.1.3.3 for trends
121 III, 10. 2. 1(7) | See Figure GPS-34 in the 2007
122 III, 10. 2. 1(8) | For further details see http ds~
123 III, 10. 2. 1 | and more highly prevalent. See Figure 10.2.1.3.6 for national
124 III, 10. 2. 1(13)| See reference (Bargagli, et
125 III, 10. 2. 1(14)| generally as limited proportion (see the 2006 statistical bulletin
126 III, 10. 2. 1(15)| See Table DRD-2 (i), Table DRD-3
127 III, 10. 2. 1(16)| See Figure DRD-1 in 2007 statistical
128 III, 10. 2. 1(19)| See Figure HSR-3 in the statistical
129 III, 10. 2. 1 | InfoBase data repository (see above).~ ~c) Reliable trend
130 III, 10. 2. 1 | adolescents~ ~The HBSC survey (see above) measured participation
131 III, 10. 2. 1 | dealt with in this Report (see section 5.2, 5.3 and 5.4),
132 III, 10. 2. 2 | details and references, see Chapter 5.2.~ ~ ~
133 III, 10. 2. 3 | details and references, see Chapter 5.2.~ ~ ~
134 III, 10. 2. 4 | rare genetic disorders (see Chapter 7 on Rare Diseases).
135 III, 10. 2. 4 | et al, 2006): by this, we see a shift from a disease-specific
136 III, 10. 2. 4 | the CYP system, we do not see any Public Health oriented
137 III, 10. 2. 4 | more than indicates that we see an increasing individualisation
138 III, 10. 2. 5 | in different age groups see Chapter 9.~ ~
139 III, 10. 3. 2 | major economic activities in SEE and the EECAA region, where
140 III, 10. 3. 2 | major “Seveso II accidents” (see below) reported for the
141 III, 10. 3. 2 | neurodevelopment disorders (see also chapters on air pollution
142 III, 10. 3. 2 | international conventions see Annex 1). Producers and
143 III, 10. 3. 2 | Asia-Europe Environment Forum. See: htt ~ ~Barbante C, et al (
144 III, 10. 3. 2 | 101). Available at: htt f; See also EU Mercury strategy
145 III, 10. 3. 3 | 10.3.3.2. Data sources~ ~See Chapter 6.~ ~
146 III, 10. 3. 3 | Control tools and policies~ ~See Chapter 6.~ ~ ~
147 III, 10. 3. 3 | 5. Future developments~ ~See Chapter 6.~ ~ ~
148 III, 10. 3. 3 | 10.3.3.6. References~ ~See Chapter 6.~ ~
149 III, 10. 4. 2 | important for hazardous agents (see also Section 4.14.2).~ ~
150 III, 10. 4. 2 | Polychlorobiphenyls~(PCBs); see textbox 4.11~ ~Oils and
151 III, 10. 4. 2 | 1996;~van Loveren, 2002; (see~textbox 4.10)~ ~ ~Mycotoxins:
152 III, 10. 4. 2 | significant health loss in DALYs (see chapter 9.1).~ ~
153 III, 10. 4. 3 | and sanitation systems (see Figure 10.4.3.2).~ ~A special
154 III, 10. 4. 3 | Brunnsregistret (in Swedish). See: htt ml~Smith AH, et al (
155 III, 10. 4. 4 | associated with piercing see Annex 1 of Chapter 5.13.~ ~
156 III, 10. 4. 4 | from the manufacturing (see Chapter 8.1.2.) and use
157 III, 10. 4. 4 | of “product” is involved (see Figure 7.23), the importance
158 III, 10. 4. 4 | and adequately enforced (see also Chapter 7). To facilitate
159 III, 10. 4. 4 | Enforcement Forum (PROSAFE) www g (see also Chapter 7).~ ~ ~
160 III, 10. 4. 5 | Environmental Assessment~SEE~South East and Eastern Europe
161 III, 10. 4. 5 | inadequate storage of chemicals (see Figure 10.4.5.2.1; EEA,
162 III, 10. 4. 5 | capita in Russia.~· the SEE countries are estimated
163 III, 10. 4. 5 | generated in the EECCA and SEE countries is growing due
164 III, 10. 4. 5 | disposal methods in EECCA and SEE is also not available. However,
165 III, 10. 4. 5 | in selected EU-25+EFTA, SEE and EECCA countries 1996-
166 III, 10. 4. 5 | EU-15. In the three largest SEE countries, Bulgaria, Romania
167 III, 10. 4. 5 | hazardous waste. All EECCA and SEE countries are party to the
168 III, 10. 5. 1 | Legionella Pneumophila (see chapter 6).~ ~Construction
169 III, 10. 5. 1 | Lebensmittelsicherheit, 2008) (see chapter 6 for fatal and
170 III, 10. 5. 2 | road accident injuries (see also Section 8.3.1.)~Different
171 III, 10. 5. 3 | provided. For fatal accidents see also Chapter 7.~ ~Table
172 III, 10. 5. 3 | member states. As we can see, a 20% reduction of accidents
173 III, 10. 5. 3 | health (for an overview see Siegrist J & Theorell T,
174 III, 10. 6. 2 | studies (for an overview see Berkman and Glass, 2000)~ ~
175 III, 10. 6. 3 | carried out in Chapter 7 (See figure 7.17).~ ~Contact
176 III, 10. 6. 3 | of offences are lacking (see Tables 9.5.5 and 9.5.6).
177 IV, 11. 1. 4 | Mossialos and Thomson 2003) (see Section 11.6 on Financing
178 IV, 11. 1. 4 | Mackenbach and Bakker 2002). See also Section 11.4.2 Public
179 IV, 11. 1. 5 | evidence based practice (EBP) (see also “Appropriateness of
180 IV, 11. 1. 5 | Hungary (less than 3.5) (See Figure 11.1). In most countries,
181 IV, 11. 1. 6 | or as a form of payment (see Table 11.3). While DRGs
182 IV, 11. 1. 6 | heavy state regulation (see Section 11.6 Financing Health
183 IV, 11. 2. 1 | beds in many countries (see below). Care outside hospitals
184 IV, 11. 3 | previous section, here we will see the issues of human resources,
185 IV, 11. 4 | can work trans-nationally. See www. eu for more information.~ ~
186 IV, 11. 5. 4 | different European countries (see Figure 11.10). These differences
187 IV, 11. 5. 5 | actively participate, please see the dedicated website (www ~ ~
188 IV, 11. 6. 2 | sharing and direct payments) (see below).~ ~European health
189 IV, 11. 6. 2 | through tax allocations (see section on Social Health
190 IV, 11. 6. 2 | Foubister and Mossialos, 2008) (see Section 11.8.3 on Progressivity).~ ~
191 IV, 11. 6. 2 | OECD data are collected (see footnote 4).~ ~Social insurance
192 IV, 11. 6. 2 | in France in the 1990s (see above). Furthermore, if
193 IV, 11. 6. 2 | Foubister and Mossialos 2008) (see below for more information
194 IV, 11. 6. 2 | out-of-pocket payments (see below). The agents collecting
195 IV, 11. 6. 4 | Robinson et al, 2005). See section 11.3.4. Technical
196 IV, 11. 6. 4 | out of his/her own pocket (see Sections on out-of-pocket
197 IV, 11. 6. 4 | politicians in this region see comprehensive and free healthcare
198 IV, 11. 6. 4 | from providers, who would see a reduction in income, being
199 IV, 12. 1 | provisions of the Treaty (see Table 12.3), related to
200 IV, 12. 2 | health in all policies (see also Chapter 11.5) and global
201 IV, 12. 2 | All Policies” principle (see Section 12.7.), and is likely
202 IV, 12. 2 | policies. For some examples, see Tables 12.4 and 12.5.~ ~
203 IV, 12. 2 | For more information see:~htt ~ ~
204 IV, 12. 5 | Information Network (EUPHIN) (see also the EUPHIN newsletter).
205 IV, 12. 5 | their collection and use (see Annex 12.1).~ ~ ~Annex 12.
206 IV, 12. 7 | policies. Yet, we have to see this principle implemented,
207 IV, 12. 10 | also at European level (see Annex 12.3). Through their
208 IV, 12. 10 | developments at Community level (see Annex 12.3).~ ~Annex 12.
209 IV, 12. 10 | within the healthcare sector.~See more: htt 8~ 2002-2010:
210 IV, 12. 10 | healthy diet and food safety~See more: htt ~ ~Physical stressors~
211 IV, 12. 10 | by Robert Koch-Institute (see www.rki.de); Drug Affinity
212 IV, 12. 10 | Centre for Health Education, see www. ). Socio-Economic Panel
213 IV, 12. 10 | study of private households, see www. l) and Census Data
214 IV, 12. 10 | Federal Statistical Office (see www. e) are other information
215 IV, 12. 10 | Public Health Reporting (see www.rki.de).~ List of ingredients
216 IV, 12. 10 | and consumer protection (see www. ).~Federal Centre for
217 IV, 12. 10 | and children/adolescents (see e. g. www o) including quit-lines (
218 IV, 12. 10 | Be smart – don’t start” (see www. ), smoke-stop competitions
219 IV, 12. 10 | WHO-initiative “Quit & Win”, see www.rauchfrei2008.de), basic
220 IV, 12. 10 | children (“Kinder stark machen” see www. ), school-based health
221 IV, 12. 10 | Cancer Research Centre (DKFZ, see www. - German Cancer Aid (
222 IV, 12. 10 | by Robert Koch-Institute (see www. e) and Drug Affinity
223 IV, 12. 10 | Centre for Health Education (see www. .~ Alcohol prevention
224 IV, 12. 10 | Bundesdrogenbeauftragte, see www.bmg.bund.de), Federal
225 IV, 12. 10 | Health Education (BzGA, see www. e) and German Center
226 IV, 12. 10 | Hauptstelle für Suchtfragen, see www. ). Several information
227 IV, 12. 10 | employees concerning alcohol (see www. ).~Detoxification,
228 IV, 12. 10 | for a list of projects see www. ~ ~Food choices and
229 IV, 12. 10 | meet the law’s criteria see www. de~National action
230 IV, 12. 10 | interviews, respectively; see http ). Dietary habits of
231 IV, 12. 10 | National Health Surveys (see www.rki.de).~ ~Nutritional
232 IV, 12. 10 | Health Education (BZgA, see www. ), Nationaler Aktionsplan "
233 IV, 12. 10 | Women and Adolescents (see www. ).~Further resources
234 IV, 12. 10 | easy-peasy” (“Kinderleicht”, see www. – supported by Federal
235 IV, 12. 10 | Protection).~“FIT KID” (see www. – healthy food at day-care
236 IV, 12. 10 | craze (“Life has weight”, see www. ), self-help projects
237 IV, 12. 10 | therapy of eating disorders (see www. – “Research association
238 IV, 12. 10 | obesity or diabetes mellitus (see above).~National governmental
239 IV, 12. 10 | according to § 20 SGB V (see above) and of different
240 IV, 12. 10 | subgroups like children, see www. e) is part of national
241 IV, 12. 10 | national health reporting (see www.rki.de).~ Selected activities:~
242 IV, 12. 10 | Bewegung und Gesundheit”, see www. – promotes “3000 footsteps
243 IV, 12. 10 | Deutschland bewegt sich, see www. – cooperation of a
244 IV, 12. 10 | Nationaler Radverkehrsplan”, see www. de or www. , “Support
245 IV, 12. 10 | Sportstättenbauförderung, see www. ~ ~Drugs and substance
246 IV, 12. 10 | Aktionsplan Drogen und Sucht, see www.bmg.bund.de) serves
247 IV, 12. 10 | Bundesdrogenbeauftragte, see www.bmg.bund.de), Federal
248 IV, 12. 10 | Health Education (BzGA, see www. e) and German Center
249 IV, 12. 10 | Hauptstelle für Suchtfragen, see www. ). Several information
250 IV, 12. 10 | Health and 8 federal states, see http .~“JES – junkies, ex-user
251 IV, 12. 10 | AIDS Support Federation, see www.jes.aidshilfe.de.~For
252 IV, 12. 10 | For further information see “Drugs and Addiction Report”
253 IV, 12. 10 | Coordinator (annually release, see www. e) and http / (European
254 IV, 12. 10 | Health Education (BZgA), (see www. e) aims to prevent
255 IV, 12. 10 | during the last 10 years (see www. ).~Institutions and
256 IV, 12. 10 | Arzneimitteltherapiesicherheit, see www. ).~Federal Institute
257 IV, 12. 10 | Medizinprodukte, BfArM, see www. e) is working on safety
258 IV, 12. 10 | der deutschen Ärzteschaft, see www. e) is an independent
259 IV, 12. 10 | online-reporting of critical events, see www. de and www. de~Institutions
260 IV, 12. 10 | Verbraucherschutz, BMELV, see www. e)~Federal Office of
261 IV, 12. 10 | Lebensmittelsicherheit, BVL, see www. – responsible for safe
262 IV, 12. 10 | für Risikobewertung, BfR, see www. - agency under public
263 IV, 12. 10 | Verbraucherzentrale Bundesverband, VZBV, see www. - umbrella organization
264 IV, 12. 10 | testing (Stiftung Warentest, see www. – independent foundation
265 IV, 12. 10 | traffic, and working safety see homepages of Federal Ministries
266 IV, 12. 10 | improve patient safety, see www. e~„Forum Patient safety“ –
267 IV, 12. 10 | Qualität in der Medizin, ÄZQ), see www. ~ ~Environmental determinants
268 IV, 12. 10 | Verbraucherschutz, BMELV, see www. e)~Federal Office of
269 IV, 12. 10 | Lebensmittelsicherheit, BVL, see www. – responsible for safe
270 IV, 12. 10 | für Risikobewertung, BfR, see www. - agency under public
271 IV, 12. 10 | Adolescents, since 04/2007, see www. e, within the framework
272 IV, 12. 10 | their health consequences”~See comments 10.2.4 and 10.2.
273 IV, 12. 10 | National Health Surveys (see www. ~ ~Genomics and public
274 IV, 12. 10 | Lebensmittelsicherheit, BVL, see www. - federal authority
275 IV, 12. 10 | usual approval procedures (see Federal Institute for Drugs
276 IV, 12. 10 | Paul-Ehrlich-Institut, see www. ). For additional information
277 IV, 12. 10 | For additional information see e. g. German Registry for
278 IV, 12. 10 | Gentherapie der Bundesärztekammer, see www. e)~Usage of stem cells
279 IV, 12. 10 | references to bioethical subjects see e. g. Federal Ministry of
280 IV, 12. 10 | by Robert Koch-Institute (see www. ~ ~B) Actions adopted
281 IV, 12. 10 | 2007~Chemicals Bills 2008~See www. ie and www. ie~Public
282 IV, 12. 10 | For further information see~http ie~Physical stressors~
283 IV, 12. 10 | Protection Agency~ ~ ~ ~See www. ie~Process of consultation
284 IV, 12. 10 | No specific regulations~ See poverty~Others~ ~ ~ ~Psychosocial
285 IV, 12. 10 | settlements~ intermediate~ ~ See air pollution and physical
286 IV, 12. 10 | Deprivation factors~ high~ ~ See poverty also: special attention
287 IV, 12. 10 | diabetes, health of youth, aids…see: htt ~ ~As regards reports,
288 IV, 12. 10 | settlements~ intermediate~ ~See air pollution and physical
289 IV, 13. 1 | magnitude (for mortality data see Table 13.3). Large differences
290 IV, 13. 4 | For further information see http ~ ~
291 IV, 13. 6. 2 | age-group paediatricians see varies in each country.
292 IV, 13. 7. 2 | environmental and societal benefits (see the LMI Communication).~ ~
293 IV, 13. 7. 5 | Throughout this report one can see the need to have comparable
